Compared to patients with exon 21 mutations, lung cancer patients harboring EGFR exon 19 deletions have both a better response rate to EGFR TKIs (70–100% vs 20–67% respectively) and improved overall survival (26–34 mos vs 8–17 mos, respectively) [21–23]. This evidence concerns the gene EGFR and lung carcinoma.